Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Underperform InterContinental Hotels Group (IHG) by Bernstein
- Add Rio Tinto (RIO) by Mark David Hartley in The Motley Fool
- Buy Tritax Big Box Reit (BBOX) by Jefferies
- Overweight easyJet (EZJ) by Barclays
- Neutral Weir Group (WEIR) by Redburn
- Buy FRP Advisory Group (FRP) by Berenberg
- Buy Grainger (GRI) by Deutsche Bank
- Hold Ashmore Group (ASHM) by Deutsche Bank
- Buy Porvair (PRV) by Berenberg
- Reduce Antofagasta (ANTO) by HSBC
- Buy BT Group (BT.A) by HSBC
- Overweight Anglo American (AAL) by JP Morgan
- Hold Rio Tinto (RIO) by HSBC
- Hold Glencore (GLEN) by HSBC
- Buy Flutter Entertainment (DI) (FLTR) by Goldman Sachs
- Neutral United Utilities Group (UU.) by Goldman Sachs
- Buy Convatec Group (CTEC) by Goldman Sachs
- Hold Imperial Brands (IMB) by Jefferies
- Buy Experian (EXPN) by Jefferies
- Buy Finsbury Growth & Income Trust (FGT) by Lauren Almeida in The Times - Tempus
Roquefort Therapeutics (ROQ) Share Price
Health Care Sector
NOTE: This is based on 0 open tips for Roquefort Therapeutics (ROQ)
| Latest Bid : 4.20p | Latest Ask : 4.50p |
| High Today : 4.35p | Low Today : 4.20p |
| This Years High : 9.25p | This Years Low : 4.00p |
| Volume : 107,337 | MKT Cap : £5.81M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Roquefort Therapeutics (ROQ) Overview
We established Roquefort Therapeutics plc to acquire businesses focused on early-stage opportunities in the medical biotechnology sector with the aim of generating optimal returns for both the target businesses and our shareholders. The investment strategy of the Company is to provide Shareholders with an attractive total return achievedprimarily through capital appreciation. The Directors believe that there are numerous investment opportunities
within both private and public businesses in the medical biotech sector in the United Kingdom, Continental
Europe and Australia.
Roquefort Therapeutics (ROQ) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 4.20p | Latest Ask : 4.50p |
| High Today : 4.35p | Low Today : 4.20p |
| This Years High : 9.25p | This Years Low : 4.00p |
| Volume : 107,337 | MKT Cap : £5.81M |
Roquefort Therapeutics Overview
We established Roquefort Therapeutics plc to acquire businesses focused on early-stage opportunities in the medical biotechnology sector with the aim of generating optimal returns for both the target businesses and our shareholders. The investment strategy of the Company is to provide Shareholders with an attractive total return achievedprimarily through capital appreciation. The Directors believe that there are numerous investment opportunities
within both private and public businesses in the medical biotech sector in the United Kingdom, Continental
Europe and Australia.
NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.